Evidence map›Paper›PMID 38001742›Full record

ArticleCancers2023

Lymph Node Molecular Analysis with OSNA Enables the Identification of pT1 CRC Patients at Risk of Recurrence: A Multicentre Study.

Karmele Saez de Gordoa, Maria Teresa Rodrigo-Calvo, Ivan Archilla, Sandra Lopez-Prades, Alba Diaz, Jordi Tarragona, Isidro Machado, Juan Ruiz Martín, Diana Zaffalon, Maria Daca-Alvarez and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Karmele Saez de GordoaPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0001-8106-6121
Maria Teresa Rodrigo-CalvoPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0001-6675-3425
Ivan ArchillaPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0002-2142-0608
Sandra Lopez-PradesPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0001-8208-2959
Alba DiazPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0002-0456-7085
Jordi TarragonaPathology Department, Hospital Arnau de Vilanova, 25198 Lleida, Spain.ORCID 0000-0002-1459-4087
Isidro MachadoPathology Department, Instituto Valenciano de Oncología, Hospital Quirón-Salud Valencia, University of Valencia, 46010 Valencia, Spain.ORCID 0000-0001-7318-1330
Juan Ruiz MartínPathology Department, Virgen de la Salud Hospital, 45071 Toledo, Spain.
Diana ZaffalonGastroenterology Department, Consorci Sanitari de Terrassa, 08227 Terrassa, Spain.ORCID 0000-0001-6099-9694
Maria Daca-AlvarezGastroenterology Department, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-5636-8865
Maria PelliséAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.
Jordi CampsAugust Pi i Sunyer Biomedical Research Institute (IDIBAPS), 08036 Barcelona, Spain.
Miriam CuatrecasasPathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain.ORCID 0000-0003-3063-0110
Hospital Clínic de Barcelona · ESCentro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas · ESConsorci Sanitari de Terrassa · ESHospital Arnau de Vilanova · ESHospital Virgen de la Salud · ESUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ESUniversitat de València · ES

Funding

Instituto de Salud Carlos III PI19/01050Instituto de Salud Carlos III PI20/00863La Marató de TV3 201932-30
6 · The paper itself

Abstract

Early-stage colorectal carcinoma (CRC)-pT1-is a therapeutic challenge and presents some histological features related to lymph node metastasis (LNM). A significant proportion of pT1 CRCs are treated surgically, resulting in a non-negligible surgical-associated mortality rate of 1.5-2%. Among these cases, approximately 6-16% exhibit LNM, but the impact on survival is unclear. Therefore, there is an unmet need to establish an objective and reliable lymph node (LN) staging method to optimise the therapeutic management of pT1 CRC patients and to avoid overtreating or undertreating them. In this multicentre study, 89 patients with pT1 CRC were included. All histological features associated with LNM were evaluated. LNs were assessed using two methods, One-Step Nucleic Acid Amplification (OSNA) and the conventional FFPE plus haematoxylin and eosin (H&E) staining. OSNA is an RT-PCR-based method for amplifying CK19 mRNA. Our aim was to assess the performance of OSNA and H&E in evaluating LNs to identify patients at risk of recurrence and to optimise their clinical management. We observed an 80.9% concordance in LN assessment using the two methods. In 9% of cases, LNs were found to be positive using H&E, and in 24.7% of cases, LNs were found to be positive using OSNA. The OSNA results are provided as the total tumour load (TTL), defined as the total tumour burden present in all the LNs of a surgical specimen. In CRC, a TTL ≥ 6000 CK19 m-RNA copies/µL is associated with poor prognosis. Three patients had TTL > 6000 copies/μL, which was associated with higher tumour budding. The discrepancies observed between the OSNA and H&E results were mostly attributed to tumour allocation bias. We concluded that LN assessment with OSNA enables the identification of pT1 CRC patients at some risk of recurrence and helps to optimise their clinical management.

Indexed as

diagnosislymph nodeOSNApT1 colorectal cancerstaging

Identifiers

PMID38001742
PMCPMC10670609
OpenAlexW4388834793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.